Tailin Pharmaceuticals (01011.HK): Kangchen Pharmaceutical has actively proposed to split the assets of the joint venture company on the basis of protecting the rights and interests of all shareholders, dissolve the joint venture relationship, and operate independently.

Zhtng Cijng APP News, Tailin Medicine (01011.HK) announced that the board of directors has received a notice from Beijing Kangchen Biotechnology Co., Ltd. (a joint venture company) and its major shareholder Beijing Kangchen Pharmaceutical Co., Ltd. (Kangchen Pharmaceutical), a company listed on the main board of the Shanghai Stock Exchange (603590.SH). Kangchen Pharmaceutical has proactively proposed to split the assets of the joint venture company and dissolve the joint venture relationship, each operating independently while protecting the rights of all shareholders.